Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Telix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.81 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 285.07 million
Earnings per share -0.218
Dividend per share N/A
Year To Date Return 75.40%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Telix Pharmaceuticals Ltd (ASX: TLX)
Latest News

TLX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.

TLX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
01 Dec 2021 $6.35 $-0.25 -3.79% 316,893 $6.55 $6.72 $6.33
30 Nov 2021 $6.60 $-0.03 -0.45% 467,617 $6.67 $6.72 $6.51
29 Nov 2021 $6.63 $-0.31 -4.47% 666,259 $6.59 $6.73 $6.46
26 Nov 2021 $6.94 $-0.20 -2.80% 204,078 $7.15 $7.15 $6.94
25 Nov 2021 $7.14 $-0.15 -2.06% 293,397 $7.28 $7.29 $7.03
24 Nov 2021 $7.29 $0.21 2.97% 401,918 $7.14 $7.30 $6.94
23 Nov 2021 $7.08 $-0.10 -1.39% 294,395 $7.20 $7.20 $6.84
22 Nov 2021 $7.18 $0.04 0.56% 297,947 $7.15 $7.31 $7.08
19 Nov 2021 $7.14 $0.16 2.29% 392,127 $7.00 $7.16 $6.86
18 Nov 2021 $6.98 $0.40 6.08% 339,929 $6.60 $6.98 $6.56
17 Nov 2021 $6.58 $0.06 0.92% 370,444 $6.56 $6.65 $6.48
16 Nov 2021 $6.52 $-0.13 -1.95% 412,481 $6.73 $6.75 $6.36
15 Nov 2021 $6.65 $-0.20 -2.92% 256,593 $6.85 $6.88 $6.60
12 Nov 2021 $6.85 $0.07 1.03% 181,619 $6.79 $6.85 $6.71
11 Nov 2021 $6.78 $-0.01 -0.15% 208,962 $6.81 $6.92 $6.72
10 Nov 2021 $6.79 $-0.28 -3.96% 454,032 $7.00 $7.01 $6.71
09 Nov 2021 $7.07 $0.15 2.17% 183,873 $6.90 $7.11 $6.80
08 Nov 2021 $6.92 $-0.40 -5.46% 440,395 $7.25 $7.28 $6.92
05 Nov 2021 $7.32 $0.18 2.52% 574,676 $7.16 $7.44 $7.15
04 Nov 2021 $7.14 $-0.06 -0.83% 636,909 $7.26 $7.45 $7.04
03 Nov 2021 $7.20 $0.02 0.28% 581,552 $7.25 $7.41 $7.09
02 Nov 2021 $7.18 $0.54 8.13% 720,333 $7.10 $7.23 $6.79

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
29 Sep 2021 Harry McCann Buy 990 $841,500
Exercise of options.
29 Sep 2021 Harry McCann Exercise 990 $841,500
Exercise of options.
29 Sep 2021 Mark Nelson Exercise 990 $841,500
Exercise of options.
29 Sep 2021 Mark Nelson Buy 990 $841,500
Exercise of options.
12 May 2021 Christian Behrenbruch Issued 100 $373,626
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Harry Kevin McCann Non-Executive ChairmanNon-Executive Director Sep 2017
Mr McCann is Chairman of China Matters. He is a Member of Champions of Change, a ProChancellor of the University of Sydney, a Trustee of the Sydney Opera House Trust and a Director of E&P Financial Services Group. Previously, he has been Chairman of Macquarie Group and Macquarie Bank Limited, Chairman of Origin Energy Limited, Healthscope Limited and ING Management Limited. He practiced as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He is a member of the Risk Committee.
Ms Jann E Skinner Non-Executive Director Jun 2018
Ms Skinner has experience in audit and accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She is an independent non-executive director of QBE Insurance Group Limited, where she also serves as Chair of the Audit Committee and Deputy Chair of the Risk & Capital Committee. She also serves as a Director of the Create Foundation Limited and HSBC Bank Australia Limited. She is a member of the Risk Committee.
Dr Christian Peter Behrenbruch Chief Executive OfficerManaging Director Jan 2017
Dr Behrenbruch has over twenty years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. He is a former Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix) and was the former Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre).
Dr Andreas Kluge Non-Executive Director Jan 2017
Dr Kluge has over 20 years of clinical research and development experience, including as Founder, General Manager and Medical Director for ABX-CRO, a full service CRO for Phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He is also Founder and was founding CEO of ABX GmbH (www.abx.de). He is further Founder, General Manager and Medical Director for Therapeia, an early stage development company in the field of neurooncology, which was acquired by Telix. He has experience in the practice of Nuclear Medicine and radiochemistry, molecular imaging and the clinical development of novel radionuclide-based products and devices. He is the author of range of patents and publications in the field of Nuclear Medicine, neurology, infection and immunology.
Mr Oliver Buck Non-Executive Director Jan 2017
Mr Buck has spent his professional career in a range of entrepreneurial and management positions in industrial companies. He has served as founder and Managing Director of range of companies in the fields of manufacturing, technology, demilitarisation, pharmaceuticals and information technologies. He is the co-founder of ITM Isotopen Technologien Munchen AG. Since 2012, he has acted as senior advisor to the CEO in a role that continues to support the ITM group as it has become a leader in next generation medical isotopes and theranostics. He is a member of the Risk Committee.
Dr Mark Alexander Nelson Non-Executive Director Sep 2017
Dr Nelson is Chairman and Co-Founder of the Caledonia Investments Group, and a Director of The Caledonia Foundation. He is Chairman of Art Exhibitions Australia, a Director of Kaldor Public Art Projects, Director of The Mindgardens Neuroscience Network, and serves as a Governor of the Florey Neurosciences Institute. Previously he was a Director of The Howard Florey Institute of Experimental Physiology and Medicine, and served on the Commercialisation Committee of the Florey Institute. He is a member of the Risk Committee.
Ms Melanie Farris Chief Governance & Risk OfficerCompany Secretary Mar 2017
-
David Cade Chief Business Officer & Head of Investor Relations
-
Melanie Farris Chief Governance & Risk OfficerCompany Secretary
-
Colin Hayward Chief Medical Officer
-
Jonathan Barlow General Counsel
-
Margaret Haarhoff Global Director of People & Culture
-
Michael Larcom Global Director of Quality
-
Doug Cubbin Group Chief Financial Officer
-
Gabriel Liberatore Group Chief Operating Officer
-
Ludovic Wouters President Telix Europe
-
Shintaro Nishimura President Telix Japan
-
Bernard Lambert President Telix US
-
Tracey Brown SVP Global Clinical Operations
-
Sunil Kadam SVP Global Regulatory Affairs
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 37,477,609 13.37%
ELK River Holdings Pty Ltd 24,675,000 8.80%
Gnosis Verwaltungsgesellschaftm B H 24,675,000 8.80%
Grand Decade Developments Limited 20,947,181 7.47%
J P Morgan Nominees Australia Pty Limited 8,371,563 2.99%
UV Cap Gmbh & Co Kg 7,775,000 2.77%
BNP Paribas Noms Pty Ltd 6,904,087 2.46%
The Oncidium Foundation 6,470,392 2.31%
National Nominees Limited 6,361,306 2.27%
Citicorp Nominees Pty Limited 6,249,988 2.23%
Scintec Diagnostics Gmbh 4,312,151 1.54%
BNP Paribas Nominees Pty Ltd 3,782,218 1.35%
UBS Nominees Pty Ltd 3,029,153 1.08%
HSBC Custody Nominees (Australia) Limited A/C 2 2,843,462 1.01%
Jean Marc Le Doussal 2,750,000 0.98%
Ilusa Sprl 2,558,138 0.91%
Yelwac Pty Ltd 2,381,804 0.85%
Man Holdings Pty Ltd 2,238,750 0.80%
Telix Pharmaceuticals (Est) Pty Ltd 2,115,000 0.75%
Aglub Investments Pty Ltd 1,933,342 0.69%
Jean Francois Chatal 1,797,795 0.64%

Profile

since

Note